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ABSTRACT
Mesenchymal stem cells (MSCs) have been demonstrated
to reside in human adult organs. However, mechanisms of
migration of these endogenous MSCs within their tissue of
origin are not well understood. Here, we investigate
migration of human adult lung-resident (LR) mesenchy-
mal progenitor cells. We demonstrate that bioactive lipid
lysophosphatidic acid (LPA) plays a principal role in the
migration of human LR-MSCs through a signaling path-
way involving LPA1-induced b-catenin activation. LR-
MSCs isolated from human lung allografts and lungs of
patients with scleroderma demonstrated a robust migra-
tory response to LPA in vitro. Furthermore, LPA levels
correlated with LR-MSC numbers in bronchoalveolar la-
vage (BAL), providing demonstration of the in vivo activ-
ity of LPA in human adult lungs. Migration of LR-MSCs
was mediated via LPA1 receptor ligation and LPA1 silenc-
ing significantly abrogated the migratory response of LR-
MSCs to LPA as well as human BAL. LPA treatment of
LR-MSCs induced protein kinase C-mediated glycogen
synthase kinase-3b phosphorylation, with resulting cyto-
plasmic accumulation and nuclear translocation of b-cate-
nin. TCF/LEF dual luciferase gene reporter assay
demonstrated a significant increase in transcriptional ac-
tivity after LPA treatment. LR-MSC migration and
increase in reporter gene activity in the presence of LPA
were abolished by transfection with b-catenin small inter-
fering RNA demonstrating that b-catenin is critical in
mediating LPA-induced LR-MSC migration. These data
delineate a novel signaling pathway through which ligation
of a G protein-coupled receptor by a biologically relevant
lipid mediator induces migration of human tissue-resident
mesenchymal progenitors. STEM CELLS 2012;30:2010–2019
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INTRODUCTION
Reparative processes in human solid organs require mobiliza-
tion of tissue-resident progenitors and migration of cells
within an organ plays an essential role in both organized and
disorganized repair. Mesenchymal cells migration, considered
to be an important first step in wound healing, is critical in
the evolution of fibrotic diseases. Infiltration of the functional
subunits by mesenchymal cells, resulting in the failure of the
organ function, is an integral part of immune-mediated
fibrotic diseases such as scleroderma. Similar pathology
ensues in the transplanted solid organs with a fibrotic graft
response to allo-immune injury presenting as bronchiolitis
obliterans syndrome (BOS) in the lungs [1], allograft vascul-
opathy in the heart, and chronic allograft nephropathy in the
kidney. While multiple origins of mesenchymal cells have
been identified, recent data suggest dominant contribution of
locally resident tissue-specific mesenchymal progenitors in
fibrogenesis [2–4]. Hence, deciphering mechanism(s) of mobi-
lization of mesenchymal progenitor with an organ is funda-
mental for understanding disorganized repair and fibrosis in
human adult solid organs.
Tissue-specific mesenchymal progenitor cells have been
demonstrated to reside in human adult organs such as lung,
heart, and kidney [4–7]. Accumulation of these multipotent
mesenchymal stem cells (MSCs) accompanies repair responses
following transplantation of the human adult lungs [8]. These
mesenchymal progenitors recruited in response to injury are
locally resident, tissue-specific cells as demonstrated by their
donor origin [7] and unique expression of embryonic lung-spe-
cific mesenchymal factors such as Forkhead box protein F1
[4]. Lung-resident MSCs (LR-MSCs), recruited in response to
injury, have also been shown to be the major contributors to
fibrogenesis in the lung allograft. However, paracrine factors,
cell surface receptors, and intracellular signaling pathways
mediating migration of endogenous organ-resident mesenchy-
mal progenitors remain to be determined.
Lysophosphatidic acid (LPA) is a bioactive lipid mediator
that exerts a wide range of cellular functions and also has
been demonstrated to induce cell migration [9, 10]. LPA sig-
nals via three closely related G protein-coupled receptors
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(GPCRs), LPA1, LPA2, and LPA3 (formerly EDG2, EDG4,
and EDG7) [11, 12]. The role of LPA in fibrotic diseases is
emerging. Studies using specific antagonists or genetic dele-
tion of LPA receptors have demonstrated an important role
for LPA in the development of kidney, lung, and skin fibrosis
in animal models [13–16]. However, the biological role of
LPA in adult human organs and the signaling mechanisms
involved in mediating its fibrotic responses remain to be fully
elucidated. b-Catenin is an integral cell-cell adhesion adaptor
protein as well as transcriptional coregulator that regulates
cell fate decisions during embryogenesis. b-Catenin plays an
essential role in the induction of mesoderm during embryo-
genesis [17, 18] and forced activation of b-catenin has been
demonstrated to increase migration and invasiveness of murine
and human mesenchymal cells [19, 20]. The best known activa-
tor of b-catenin is Wnt-1 that leads to the accumulation of a
cytoplasmic-free pool of b-catenin, which then translocates into
the nucleus and binds to transcription factors of the lymphoid-
enhancer-factor/T-cell-factor (LEF-1/TCF) family to regulate
b-catenin/LEF/TCF-dependent gene expression [21]. However,
recent studies indicate that various other ligands can also poten-
tially activate the b-catenin pathway [22].
Here, we demonstrate what we believe to be a previously
unknown mesenchymal cell signaling pathway triggered by
LPA interaction with GPCR LPA1 in human LR-MSCs. This
pathway involves protein kinase C (PKC)-mediated phospho-
rylation of glycogen synthase kinase-3b (GSK3b) at Ser-9
leading in turn to cytoplasmic b-catenin accumulation and nu-
clear translocation. One of the biological effects of this LPA-
mediated activation of the b-catenin pathway, shown here, is
the induction of cell migration.
MATERIALS AND METHODS
Isolation of LR-MSCs from Bronchoalveolar Lavage
LR-MSCs were isolated from bronchoalveolar lavage (BAL) fluid
of lung transplant recipients with no evidence of rejection or
infection and scleroderma patients under a protocol approved by
the Institutional Review Board of the University of Michigan as
previously described [4, 7, 8]. Briefly, mesenchymal colony-form-
ing units (CFUs) were isolated and expanded from the adherent
culture of BAL cells. Cells were maintained in high-glucose Dul-
becco’s modified Eagle’s medium supplemented with 10% fetal
bovine serum (FBS), 100 U/ml penicillin/streptomycin and 0.5%
fungizone (Invitrogen, Carlsbad, CA) at 37C and 5% CO2/95%
air. Flowcytometric analysis demonstrated positive expression of
cell surface markers CD73, CD105, CD90, and CD44 and nega-
tive expression of hematopoietic markers CD45. Multilineage dif-
ferentiation potential was confirmed by induction into other mes-
enchymal lineages such as osteocytes, adipocytes, and
chondrocytes as previously demonstrated [4, 7, 8]. All cells used
for experiments were between passages 3 and 6.
RNA Isolation and Analysis
Total RNA was isolated from LR-MSCs using the RNeasy mini kit
(Qiagen, Inc., Valencia, CA) as per manufacturer’s instructions.
Real-time reverse transcriptase polymerase chain reaction (RT-PCR)
assay was performed using a one-step real-time RT-PCR kit
(Applied Biosystems, Foster City, CA) as per manufacturer’s proto-
col. TaqMan gene expression assay primers for LPA-1, LPA-2, and
LPA-3 were purchased from Applied Biosystems (Hs00173500_m1,
Hs00173704_m1, and Hs00173857_m1, respectively).
Protein Isolation and Western Blot Analysis
LR-MSCs whole cell lysates were collected using cell lysis buffer
purchase from Cell Signaling Technologies (Danvers, MA).
LR-MSCs nuclear and cytoplasmic extracts were collected using
NXTRACT kit (Sigma, St. Louis, MO) as per manufacturer’s
protocol. Proteins from whole cell or nuclear extracts were sepa-
rated by electrophoresis in a 10% Bis-Tris polyacrylamide gels
and transferred onto polyvinylidine fluoride (PVDF) membranes
(Invitrogen). Immunoblotting was done using primary antibodies
against LPA-1, b-catenin, p-GSK3b, glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) (all from Abcam, Cambridge, MA),
SAM68 (Santa Cruz Biotechnology, Santa Cruz, CA), and horse-
radish peroxidase-conjugated secondary antibodies (Sigma, St.
Louis, MO). Signal was developed using pico or dura kit from
Thermo Scientific (Rockford, IL).
Cell Migration Assay
Cells’ ability to migrate was assessed using Matrigel-coated (8
lm) transwells chamber setup purchased from BD biosciences
(San Jose, CA). LR-MSCs or normal lung fibroblast (CCL-210)
(ATCC, Manassas, VA) were seeded in transwells (upper chamber)
at 1  105 cells per 200 ll serum-free media and placed into 24-
well plates containing 600 ll serum-free media that were supple-
mented with or without LPA (Cayman, Ann Arbor, MI), FBS, pla-
telet-derived growth factor (PDGF), stromal cell-derived factor
(CXCL12), hepatocyte growth factor (HGF), C-C motif ligand 21
(CCL21), epidermal growth factor (EGF), formyl-methionyl-
leucyl-phenylalanine, lipoteichoic acid, C-C Motif Ligand 19
(CCL19) (all from Sigma), or BAL supernatant at the specified
concentrations. For migration assays where LPA-1/LPA-3 or con-
ventional PKC (cPKC)-specific antagonists were used, cells were
treated with 10 lM of either VPC12249 or VPC32183 (Avanti Po-
lar Lipids, Alabaster, AL) or 1 lM of GO¨6906 (Calbiochem, San
Diego, CA), respectively, for 30 minutes before they were seeded
into the upper chamber. After 4 hours, cells that were migrated
through transwells and attached on the surface underneath were
fixed and stained using Hema 3 staining kit (Fisher Scientific,
Kalamazoo, MI) and washed with water. Transwells’ upper surface
was cleaned with cotton swabs to remove any remaining cells and
transwells were left to dry. Transwells’ surface was removed and
mounted on slides and examined under a microscope. Cells were
counted (five high power fields per transwell) and results were pre-
sented as average number of cells migrated per high power field
per transwell. All experiment conditions were set up in triplicates.
BAL LPA Analysis
Lipids were extracted from BAL fluid using solid-phase extraction
column technique. Briefly, BAL fluid was applied to precondi-
tioned C18 Sep-Pak columns (Waters, Milford, MA). Columns
were washed with buffer followed by water. Lipids were eluted
with 80% methanol and 20% ddH2O, dried under nitrogen in the
evaporator, and frozen at 20C. LPA concentration was measured
in eluted samples using LPA ELISA kit from Echelon Biosciences
(Salt Lake City, UT) according to manufacturer’s protocol.
Small Interfering RNA
Small interfering RNA (siRNA) targeting b-catenin, LPA-1 receptor,
and nontargeting scrambled siRNA were purchased from Applied
Biosystems. LR-MSCs were transiently transfected with siRNA
using oligofectamine (Invitrogen, Carlsbad, CA) for 24 hours and se-
rum starved for another 24 hours before any treatment was added.
TCF/LEF Luciferase Reporter Assay
LR-MSCs were transfected with an inducible dual luciferase re-
porter plasmid containing TCF/LEF DNA binding sites, negative
control (a noninducible luciferase construct used to eliminate
background), or positive control (a green fluorescent protein
expressing construct used for visual confirmation and optimiza-
tion of transfection) vector using oligofectamine according to
manufacturer’s protocol. To determine b-catenin activity, LR-
MSCs were cotransfected with b-catenin or nontargeting siRNA.
Cells were serum starved for 24 hours before they were stimu-
lated with LPA (10 lM) for 2 hours. Reporter activity was
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assayed using the dual luciferase system from Promega (Madison,
WI) according to manufacturer’s protocol.
RESULTS
LPA Induces Migration of Human LR-MSCs
Via LPA1 Receptor
LR-MSCs were isolated from the BAL fluid of human lung al-
lografts as previously described [7]. The effect of LPA on
LR-MSC migration was first evaluated in vitro using a modi-
fied Boyden chamber. Migration was quantified by staining the
migratory cells on the lower side of insert membrane. A dose-
dependent migration of human LR-MSCs was noted in the
presence of LPA (Fig. 1A). Effect of LPA on LR-MSC migra-
tion was compared to that of other known cellular chemo-at-
tractants (Fig. 1B). A significant migratory response of
LR-MSCs was noted in response to LPA, EGF, and HGF.
However, LPA-induced migration was significantly higher than
that for either EGF (p < .001) or HGF (p < .001). The
migratory response of LR-MSCs to LPA was noted to be
significantly higher when compared with normal human lung
fibroblasts (CCL-210). A 2.5-fold increase in migration was
noted in human lung fibroblast in response to LPA (p ¼ .014).
In comparison, LPA induced a 14-fold increase in migration of
human LR-MSCs (p < .0001). These data establish LPA as a
highly potent inducer of human LR-MSC migration.
LPA1 was found to be the predominant receptor expressed
on human LR-MSCs with a 4,726- and 9,311-fold higher expres-
sion of LPA1 mRNA noted as compared to LPA2 and LPA3,
respectively (Fig. 1C). LPA1 receptor expression was also con-
firmed at protein level by Western blot analysis and immuno-
staining (Fig. 1C). LPA1/LPA3 antagonists (VPC12249 and
VPC32183) markedly diminished LPA-induced migration of
LR-MSC without effecting PDGF or 10% FBS-induced migra-
tion (Fig. 1D). As neither of these pharmacological inhibitors is
specific for LPA1 receptor only, the results were further con-
firmed with siRNA directed toward LPA1 receptor. LPA1
siRNA transfection of LR-MSCs was associated with a greater
than 80% reduction in LPA1 protein expression (Fig. 1E) and a
95% decrease in LPA-induced migration of LR-MSCs (Fig. 1F),
demonstrating that LPA1 is the predominant receptor mediating
LPA-induced migration of LR-MSCs. LPA1 siRNA had no
effect on PDGF and FBS-induced migration (Fig. 1F).
Human BAL LPA Levels Correlate with LR-MSC
Numbers and BAL-Induced Migration of MSCs
Is Inhibited by LPA1 Antagonists
To investigate the in vivo role of LPA in inducing LR-MSC
migration in human lungs, correlation of LPA with number of
LR-MSCs in BAL was examined. LPA levels were measured
in the supernatant from the BAL samples derived from human
lung allografts. Mesenchymal CFUs were quantitated in the
cell pellet from the same BAL samples as previously
described [8]. A significantly higher LPA concentration was
noted in BAL fluid from lung transplant patients with high
CFU count (CFU per 2  106 cell 10) as compared to those
with low CFU count (CFU per 2  106 cell <10) (Fig. 2A).
This CFU level cutoff was determined based on our previ-
ously published data [8]. CFU count as a continuous variable
also correlated significantly with LPA levels (r ¼ 0.63; p ¼
.007). Next, cell migration assay was performed using BAL
fluid as a chemoattractant. Supernatant from BAL with high
mesenchymal CFUs but not from those with low mesenchy-
mal CFUs induced significant LR-MSCs migration in vitro
(Fig. 2B). This migratory effect of supernatant from BAL
samples with high CFUs on LR-MSCs was completely abol-
ished in the presence of LPA1/LPA3 antagonist, VPC12249
(Fig. 2B). These data demonstrate that LPA accounts for the
majority of mesenchymal cell migratory activity of BAL from
human lung allografts, findings which are compatible with
data from patients with idiopathic pulmonary fibrosis [16].
LPA-Induced Migration of LR-MSCs Is Dependent
on the b-Catenin Pathway
b-Catenin is an important component of the cell cytoskeleton
and a key player in the signaling mechanisms that regulates
cell migration in response to Wnt pathway ligands [23]. Acti-
vation of the canonical Wnt signal transduction pathway in
MSCs and forced activation of b-catenin signaling in human
and murine mesenchymal cells have been shown to impart
increased motility and invasiveness [19, 20, 24].
Investigation of the intracellular signaling pathways acti-
vated by LPA receptor ligation demonstrated a robust cyto-
plasmic b-catenin accumulation with LPA treatment (Fig.
2C). To investigate whether b-catenin activation is responsible
for LPA-induced LR-MSCs migration, cells were transfected
with b-catenin siRNA and their migratory response was inves-
tigated. Measurement of b-catenin protein expression in ali-
quots of transfected cells confirmed the efficacy of silencing
with a significant (85%) reduction in protein expression
seen in the presence of b-catenin siRNA (Fig. 2D). As shown
in Figure 2E, b-catenin silencing significantly abrogated LR-
MSCs migration in response to LPA with mean number of
migrating LR-MSCs decreasing from 64.89 6 7.53 to 8.38 6
7.29 per high power field (p < .0001). b-Catenin siRNA did
not inhibit PDGF or 10% FBS-induced migration.
LPA Induces GSK3b Phosphorylation and
b-Catenin Nuclear Accumulation and Promotes
b-Catenin-Induced Transcription in LR-MSCs
b-Catenin levels in the cytoplasm are tightly regulated by its
phosphorylation, ubiquitination, and proteosomal degradation
[25]. GSK3b interacts with adenomatous polyposis coli and axin
proteins to form a destruction complex that phosphorylate b-cat-
enin and makes it a target for proteasome-mediated degradation.
Phosphorylation of GSK3b at Ser-9 causes inhibition of its activ-
ity resulting in cytoplasmic b-catenin accumulation, nuclear
translocation, and TCF/LEF target genes transcription activation.
To investigate whether LPA-induced b-catenin upregulation is
the result of GSK3b inhibition, we studied the effect of LPA on
GSK3b phosphorylation at Ser-9. As shown in Figure 3A, LPA
treatment was associated with a significant increase in GSK3b
phosphorylation, thus explaining the increase in cytoplasmic b-
catenin expression with LPA treatment. Thirty minutes after
LPA stimulation, a significant elevation in the b-catenin protein
level in the nuclear fraction was noted (Fig. 3B). Nuclear b-cate-
nin protein levels peaked at 1 hour and were still significantly
elevated at 4 hours. TCF/LEF dual luciferase gene reporter assay
performed 2 hours after LPA treatment demonstrated a signifi-
cant increase in transcriptional activity. The increase in reporter
gene activity in response to LPA was completely abolished
when b-catenin siRNA were used (Fig. 3C). These findings sug-
gest that LPA stimulation of LR-MSCs leads to GSK3b phos-
phorylation, which inhibits b-catenin degradation and leads to
b-catenin pathway activation.
LPA1 Ligation-Mediated b-Catenin
Activation in LR-MSCs
The predominant expression of LPA1 on LR-MSCs and the
role of this receptor in mediating LPA-induced LR-MSC
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Figure 1. LPA induces migration of human lung-resident mesenchymal stem cells (LR-MSCs) via LPA1 receptor. (A, B): LPA induces LR-MSC
migration in a dose-dependent manner. Human LR-MSCs were added to the upper chamber of the Transwell and allowed to migrate through the porous
membrane into the lower chamber containing medium alone or medium with LPA. Migrated cells on the lower side of the membrane were stained with
Hema3 stain and counted with Olympus BX41 light microscope using a 20 objective. n ¼ 3 separate cell lines with three replicates of each condition
and five counted high power fields for each replicate. Representative image from transwell demonstrating robust migration of LR-MSCs in response to
LPA is shown above. LPA-induced migration was compared to that induced by 10 ng/ml CCL21, 30 ng/ml CXCL12, 10 ng/ml EGF, 20 ng/ml HGF, 0.1
lM FMLP, 1 lg/ml LTA, 10% FBS, and 10 nM PDGF, as shown in (B). n ¼ 4 individual cell lines with three replicates of each condition and five
counted high power fields for each replicate. (C): LPA receptors profile of human LR-MSCs. LPA1, LPA2, and LPA3 mRNA expression by real-time
quantitative PCR in human LR-MSCs. n¼ 4 LR-MSC lines. A representative image fromWestern blot analysis and immunofluorescent staining demon-
strating LPA1 protein expression in LR-MSCs is shown below. (D): Effect of LPA receptor antagonists on LPA-induced LR-MSC migration. LR-MSCs
were pretreated with competitive antagonists of the LPA1 and LPA3 receptors (1 lM VPC12249 or 1 lM VPC32183) for 30 minutes before migration
assay. Data represent mean6 SEM from three independent experiments. (E, F): Effect of LPA1 siRNA on LPA-induced migration of human LR-MSCs.
LR-MSCs were transfected with (20 nM) validated LPA1 or scrambled siRNA for 24 hours and serum starved for another 24 hours. Protein was collected
for Western blot analysis to test transfection efficiency as shown in (E) (n ¼ 3). Effect of LPA1 siRNA on LR-MSC migration was studied using the
migration assay. Data shown in (F) represent mean6 SEM from three independent experiments. **, p< .01; ***, p< .001. Abbreviations: CCL21, C-C
motif ligand 21; DMEM, Dulbecco’s modified Eagle’s medium; EGF, epidermal growth factor; FBS, fetal bovine serum; FLMP, Formyl-methionyl-
leucyl-phenylalanine; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HGF, hepatocyte growth factor; LPA, lysophosphatidic acid; PDGF, plate-
let-derived growth factor; siRNA, small interfering RNA.
Figure 2. Demonstration of the in vivo role of LPA in human lung allografts and the role of b-catenin activation in mediating LPA-induced lung-
resident mesenchymal stem cell (LR-MSC) migration. (A): Correlation of LPA concentration with number of LR-MSC in human BAL fluid. LR-
MSCs were quantitated in BAL fluid from human lung transplant recipients by measuring number of mesenchymal CFUs per 2  106 million cells.
LPA concentration in supernatant of these BAL samples with high CFUs (CFU  10, n ¼ 10) and low CFUs (CFU <10, n ¼ 10) was determined.
(B): LPA accounts for chemotactic activity of BAL derived from human lung allografts. Ability of supernatant from samples with high and low
CFUs to induce LR-MSC and its modulation by LPA receptor antagonist (VPC12249) was assessed by Transwell assay. Two LR-MSC lines
(6VPC12449) were exposed to supernatant from four BAL samples with high CFUs (CFUs of 40, 13, 13, and 50) and four BAL samples with low
CFUs (CFUs of 2, 0, 0, and 0). Data are shown as mean 6 SEM of migration induced by these BAL samples. Control signifies plain Dulbecco’s
modified Eagle’s medium. (C): Effect of LPA treatment on b-catenin protein expression in human LR-MSCs. Serum-starved LR-MSCs were treated
with 10 lM LPA for various time points. b-Catenin protein expression in the cytoplasmic fraction was quantitated by Western blot analysis. Data
represent mean 6 SEM from four individual LR-MSC lines. (D, E): Effect of b-catenin siRNA on LPA-induced LR-MSC migration. LR-MSCs
were transfected with b-catenin siRNA (20 nM) or scrambled siRNA for 24 hours. b-Catenin protein was measured by Western blot analysis in ali-
quots of transfected cells as shown in (D). Panel (E) demonstrates the effect of b-catenin silencing on LR-MSC migration in response to LPA and
other control chemoattractants (10% FBS and PDGF), studied using the Transwell migration assay. Data represent mean 6 SEM from four individual
experiments. **, p < .01; ***, p < .001. Abbreviations: BAL, bronchoalveolar lavage; CFU, colony-forming unit; FBS, fetal bovine serum; GAPDH,
glyceraldehyde 3-phosphate dehydrogenase; LPA, lysophosphatidic acid; PDGF, platelet-derived growth factor; siRNA, small interfering RNA.
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Figure 3. LPA induces GSK3b phosphorylation and activates b-catenin pathway. (A): Effect of LPA treatment on GSK3b phosphorylation.
Serum-starved lung-resident mesenchymal stem cells (LR-MSCs) were treated with 10 lM LPA for 30 or 60 minutes. GSK3b phosphorylation
was studied by Western blot analysis using phospho-specific antibody (phospho-Ser-9) against GSK3b. n ¼ 4. (B): LPA induces nuclear trans-
location of b-catenin. Nuclear protein fractions of LR-MSCs treated with LPA were used to detect nuclear b-catenin accumulation by Western
blot analysis. Results were normalized to nuclear SAM68 as a nuclear loading control. n ¼ 4. (C): TCF/LEF/b-catenin transcription activation
by LPA. LR-MSCs were transfected with TCF/LEF luciferase reporter construct (an inducible luciferase reporter), negative control (a nonindu-
cible luciferase reporter used for background elimination), or positive control vector (a green fluorescent protein expressing luciferase
construct used to test transfection efficiency, data not shown) using oligofectamine. In some conditions, LR-MSCs were also cotransfected
with b-catenin siRNA (20 nM). Transfected cells were then treated with either control vehicle or 10 lM LPA for 2 hours. Reporter activity
was assayed using dual luciferase assay system and data are shown as fold induction in RLU. Experiments were done in triplicates. n ¼ 5
LR-MSC lines. (D, E): LPA1 receptor is the key receptor in LPA activation of b-catenin pathway. LR-MSCs were transiently transfected with
(20 nM) LPA1 siRNA for 24 hours before treatment with 10 lM LPA. Total protein was collected at various time points after LPA treatment
and analyzed for GSK3b phosphorylation by Western blot analysis. b-Catenin protein expression in nuclear fractions 1 hour after LPA is
shown in (E). n ¼ 3. **, p < .01; ***, p < .001. Abbreviations: TCF/LEF, lymphoid-enhancer-factor/T-cell-factor; GAPDH, glyceraldehyde
3-phosphate dehydrogenase; GSK3b, glycogen synthase kinase-3b; LPA, lysophosphatidic acid; RLU, relative light units.
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migration led us to evaluate whether LPA activation of b-cat-
enin pathway is mediated by LPA1 receptor. To investigate
this, GSK3b phosphorylation and nuclear expression of b-cat-
enin were measured in LPA-stimulated LR-MSCs with and
without siRNA directed toward LPA1 receptor. LPA1 silenc-
ing significantly inhibited LPA-induced GSK3b phosphoryla-
tion (Fig. 3D) and nuclear b-catenin protein expression (Fig.
3E), suggesting that LPA1 receptor is the key receptor media-
ting LPA activation of b-catenin pathway in human LR-
MSCs.
LPA Induced GSK3b Phosphorylation and
b-Catenin Nuclear Translocation, and Migration of
LR-MSCs is Mediated Via PKC Activation
A primary response of most cell types to LPA is phospholi-
pase C (PLC) activation, which results in IP3 and diacylglyc-
erol production with consequent intracellular calcium mobili-
zation and PKC activation. cPKC-specific inhibitor GO¨6976
was found to abolish LPA-induced GSK3b phosphorylation
and strongly inhibited nuclear accumulation of b-catenin (Fig.
4A, 4B). The migratory effect of LPA on LR-MSCs was also
abrogated in the presence of GO¨6976 (Fig. 4C). These results
suggest that cPKC activation mediates the LPA-induced phos-
phorylation of GSK3b leading to b-catenin nuclear transloca-
tion and subsequent cell migration.
LPA Causes Migration of Scleroderma LR-MSCs
Via an LPA1-Mediated Phosphorylation and
Inhibition of GSK3b and Subsequent
b-Catenin Translocation
To investigate the robustness of the data and to determine the
importance of this signaling pathway in other immune-
Figure 4. LPA-induced conventional PKC (cPKC) activation is essential for LPA-induced b-catenin pathway activation and migration. Serum-
starved lung-resident mesenchymal stem cells were pretreated with specific cPKC inhibitor (GO¨6976) for 30 minutes before treatment with
10 lM LPA. The effect of cPKC inhibitor on GSK3b phosphorylation (A) and nuclear b-catenin expression (B) was studied by Western blot
analysis. Cell migration (C) was assayed in the presence of cPKC inhibitor. n ¼ 4. *, p < .05; **, p < .01; ***, p < .001. Abbreviations:
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GSK3b, glycogen synthase kinase-3b; LPA, lysophosphatidic acid; PKC, protein kinase C.
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Figure 5. LPA causes migration of scleroderma lung-resident mesenchymal stem cells (LR-MSCs) via an LPA1-mediated phosphorylation and
inhibition of GSK3b and subsequent b-catenin translocation. (A, B): LPS induces robust migration of scleroderma lung-derived MSCs. Migration
of LR-MSCs derived from patients with scleroderma in response to varying doses of LPA was assessed in vitro using transwell system. LPA-
induced migration was compared to that induced by 10% FBS and 10 nM platelet-derived growth factor as shown in (B). (C): LPA1 is the pre-
dominant receptor of scleroderma lung-derived MSCs. mRNA expression of LPA receptors by real-time quantitative PCR in scleroderma LR-
MSCs is shown. (D–F): LPA1 receptor mediates LPA-induced migration of scleroderma lung-derived MSCs. Effect of LPA receptor antagonists
on LPA-induced LR-MSC migration was studied by pretreating cells with competitive antagonists of the LPA1 and LPA3 receptors (1 lM
VPC12249) for 30 minutes before migration assay. Furthermore, effect of LPA1 siRNA on LPA-induced migration of human LR-MSCs was
studied. (G, H): LPA induces GSK3b phosphorylation and nuclear translocation of b-catenin in scleroderma lung-derived MSCs. Serum-starved
LR-MSCs were treated with 10 lM LPA. GSK3b phosphorylation was studied by Western blot analysis using phospho-specific antibody (phos-
pho-Ser-9) against GSK3b. Nuclear protein fractions of LR-MSCs treated with LPA were used to detect nuclear b-catenin accumulation by West-
ern blot analysis. Results were normalized to nuclear SAM68 as a nuclear loading control. (I): LPA-induced migration of scleroderma lung-
derived MSCs is dependent on the b-catenin pathway. LR-MSCs were transfected with b-catenin siRNA (20 nM) or scrambled siRNA for 24
hours. Effect of b-catenin silencing on LR-MSC migration in response to LPA was studied using the Transwell migration assay. n ¼ 3 sclero-
derma cell lines. *, p < .05; **, p < .01; ***, p < .001. Abbreviations: FBS, fetal bovine serum; GAPDH, glyceraldehyde 3-phosphate dehydro-
genase; GSK3b, glycogen synthase kinase-3b; LPA, lysophosphatidic acid; siRNA, small interfering RNA.
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mediated fibrotic diseases, we investigated this mechanism of
migration in MSCs isolated from the lungs of patients with
scleroderma. LR-MSCs isolated from BAL of patients with
scleroderma demonstrated migratory response to stimulation
by LPA in a robust and dose-dependent manner (Fig. 5A,
5B). LPA1 was found to be the predominant LPA receptor
and the role of LPA1 in mediating migratory response to LPA
was demonstrated using chemical inhibition and siRNA
approach (Fig. 5C–5F). The role of b-catenin activation in
LPA-induced migration of scleroderma LR-MSCs was estab-
lished by GSK3b phosphorylation and b-catenin nuclear trans-
location in response to LPA stimulation (Fig. 5G, 5H) and
demonstration of complete abrogation of migration with b-
catenin siRNA (Fig. 5I).
DISCUSSION
Delineation of embryonic lung mesenchyme and expression of
mesenchyme-specific transcription factors is essential for branch-
ing morphogenesis and epithelial cell specification in the fetal
lung [26]. We have recently demonstrated that lung-specific mes-
enchymal progenitors reside in the human adult lung [4, 7]. These
LR-MSCs express embryonic lung-specific mesenchymal factors
such as FOXF1 [4] and can modulate lung epithelium via para-
crine mechanisms such as secretion of keratinocyte growth factor
as well as via direct gap junction communications [27]. An
increase in LR-MSC population is seen in response to injury such
as after adult lung transplantation in humans [8] and likely plays a
role in lung repair. LR-MSCs can also differentiate into myofibro-
blasts in response to profibrotic factors such as transforming
growth factor-b and an altered profibrotic phenotype is noted in
LR-MSCs derived from lungs in diseases such as bronchiolitis
obliterans [4]. Mobilization of the LR-MSC population to lung
airspaces precedes development of chronic allograft rejection or
BOS [8]. Here, we investigate the signaling pathways mediating
migration of these endogenous organ-resident mesenchymal pro-
genitors. We demonstrate that ligation of GPCR LPA1 leads to
migration of LR-MSCs via GSK3b phosphorylation and subse-
quent b-catenin accumulation and nuclear translocation. These
data suggest an important role for b-catenin activation in mobili-
zation of tissue-resident mesenchymal progenitors.
Mechanism(s) of migration of MSCs has garnered signif-
icant attention secondary to the potential of using exoge-
nously administered or endogenously recruited bone mar-
row-derived MSCs (BM-MSCs) for tissue repair in solid
adult organs [28, 29]. These studies have identified several
chemokines and growth factors as chemoattractants for BM-
MSC in vitro. However, this study investigates migration of
endogenous adult organ-resident MSCs, a cellular population
that has been demonstrated to be distinct from BM-MSCs.
In this first investigation of migratory function of organ-resi-
dent MSCs, MSCs derived from human adult lungs demon-
strated a robust migration in response to LPA. Furthermore,
correlation of LPA levels with number of LR-MSCs in the
human lung lavage samples and the ability of LPA1 receptor
antagonism to abolish the migratory response of LR-MSCs
to BAL provide demonstration of its in vivo activity in
human adult lungs.
A novel aspect of this study is that it identifies LPA1 re-
ceptor ligation as an activator of b-catenin pathway in
human LR-MSCs. This finding links a key lipid mediator
with a key intracellular protein, both of which have been
independently demonstrated to be important in both develop-
ment and disease pathogenesis. b-Catenin is essential for de-
velopment of mesenchyme during embryogenesis [17, 18].
In adults, activation of b-catenin pathway has been demon-
strated to play a key role in migration and invasiveness of
various human cancer cell lines [30]. b-Catenin has also
been implicated in fibrosis with migration of fibroblasts
induced by forced activation of b-catenin [19, 20]. Similarly,
LPA is linked to invasiveness of cancer cells and data from
animal studies demonstrate a key role for LPA in the devel-
opment of pulmonary, liver, and renal fibrosis [13–16]. How-
ever, the mechanism of how inhibition of LPA1 receptor
engagement mediates these effects is fully understood. Our
study of human LR-MSCs demonstrates that LPA1 receptor
ligation leads to GSKb phosphorylation and subsequent nu-
clear translocation of b-catenin. This finding also has impor-
tant implications in a disease like scleroderma where while
b-catenin activation has been described in skin and lung
mesenchymal cells, [17] the ligand(s) causing that have not
been identified.
Activation of b-catenin by non-WNT pathway ligands has
garnered significant interest and several physiologically rele-
vant mediators capable of signaling to the canonical b-catenin
have been identified in specific cells [22]. LPA has been pre-
viously reported to induce proliferation of colon cancer cells
via activation of b-catenin pathway [31]. However, LPA2 was
the most abundantly expressed receptor and mediated the
effect of LPA on proliferation in colon cancer cells. Further-
more, LPA2 and LPA3 but not LPA1 was shown to activate
b-catenin pathway [31]. This is in contrast to our observation
that LPA1 receptor ligation activates b-catenin pathway and
induces cell migration. LR-MSC, unlike colon cancer cells,
demonstrated predominant expression of LPA1 in comparison
to LPA2 or LPA3. Silencing LPA receptor not only abolished
LPA-induced MSCs migration but also prevented LPA-
induced GSK3b phosphorylation and nuclear translocation of
b-catenin. Common to both these studies was the finding that
PKC activation mediates GSK3b phosphorylation. This is not
surprising as both LPA1 and LPA2 have been demonstrated
to be potent inducers of PLC activation in embryonic fibro-
blasts [32]. Thus, our study not only demonstrates the role of
LPA1 ligation in b-catenin activation for the first time but
also establishes the applicability and biological consequences
of the phenomenon of b-catenin activation by GPCRs in non-
transformed primary human cells. However, while our studies
using b-catenin downregulation by siRNA demonstrate that b-
catenin mediates the migratory effect of LPA on LR-MSCs,
these studies do not elucidate whether this effect is mediated
via its effects on structural organization and cadherin/b-cate-
nin interaction or via its activation of nuclear transcription
factors of the TCF/LEF family [23, 33, 34]. These studies
will be the subject of future investigation.
CONCLUSION
In summary, our studies have defined what we believe to be
a previously unknown mesenchymal signaling pathway trig-
gered by LPA interaction with GPCR LPA1. This pathway
involves PKC-mediated phosphorylation of GSK3b at Ser-9
that in turn leads to cytoplasmic b-catenin accumulation and
nuclear translocation. Stabilization of b-catenin then acti-
vates transcription of Lef/Tcf target genes. One of the bio-
logical effects of this LPA signaling cascade is enhancement
of cell migration. Collectively, these data offer novel insight
into the mechanism of recruitment of endogenous mesenchy-
mal progenitor cells and provide a mechanistic explanation
for the important role of LPA in pathogenesis of tissue fibro-
sis [13–16].
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